Unveiling the Prognostic Power of Circulating Tumor DNA in Multiple Myeloma: A Systematic Review and Updated Meta-Analysis.

Cancer MedSep 29, 2026
Clinical ResearchOncology (Medical)Pathology (Anatomic & Clinical)

Wanting Ying, Lei Fan, Ran Li et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prognostic significance of circulating tumor DNA (ctDNA) in 948 patients with multiple myeloma (MM). The study found that detectable ctDNA is associated with a significantly increased risk of aggressive disease progression (HR, 3.21) and reduced overall survival (OS) (HR, 3.97).

Key findings

  • Patients with detectable ctDNA had a 3.21 times higher risk of aggressive disease progression.
  • Detectable ctDNA was associated with a 3.97 times increased risk of reduced overall survival.
  • Subgroup analyses showed ctDNA positivity correlated with poorer OS in relapsed or refractory MM patients.
  • Associations were not significant in newly diagnosed MM or among Asian patients.

Why it matters

The findings highlight the potential of ctDNA as a non-invasive biomarker for assessing prognosis in multiple myeloma, which could aid in risk stratification and treatment planning.

Source

PubMed · PMID 42802646

Published in Cancer Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.